Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease
- 주제(키워드) Inflammatory bowel disease , anti-tumor necrosis factor , BCG , infant
- 주제(기타) Gastroenterology & Hepatology
- 설명문(일반) [Park, Sang Hyoung; Ye, Byong Duk; Yang, Suk-Kyun] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea; [Kim, Hyo Jong; Lee, Chang Kyun] Kyung Hee Univ, Ctr Crohns & Colitis, Dept Gastroenterol, Coll Med, Seoul, South Korea; [Song, Eun Mi; Jung, Sung-Ae] Ewha Womans Univ, Dept Internal Med, Sch Med, 260 Gonghangdae Ro, Seoul 07804, South Korea; [Kang, Sang-Bum] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Gastroenterol,Daejeon St Marys Hosp, Daejeon, South Korea; [Jang, Byung Ik; Kim, Kyeong Ok] Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; [Kim, Eun Soo] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; [Lee, Yoo Jin] Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea; [Kim, Eun Young] Catholic Univ, Dept Internal Med, Daegu Sch Med, Daegu, South Korea; [Jung, Yun Jin] Daegu Fatima Hosp, Dept Internal Med, Daegu, South Korea; [Park, Soo-Kyung; Il Park, Dong] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Gastroenterol,Sch Med, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 OXFORD UNIV PRESS
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000175464
- 본문언어 영어
- Published As http://dx.doi.org/10.1093/ecco-jcc/jjaa099
- PubMed https://pubmed.ncbi.nlm.nih.gov/32417881
초록/요약
Backgrounds and Aims: We aimed to evaluate the safety of Bacille Calmette-Guerin [BCG] vaccination in infants born to mothers receiving anti-tumour necrosis factor [anti-TNF] therapy for inflammatory bowel disease. Methods: Adverse events of BCG vaccination were evaluated in 90 infants who were last exposed to anti-TNF agents at a median of gestational week 30. Results: After receiving BCG vaccination at a median age of 6 months [range, 0.25-11 months], three infants [3.3%] showed injection site swelling, two of whom also showed axillar lymphadenopathy. The rates of adverse events were similar between infants who were last exposed to anti-TNF agents before the third trimester [n = 35] and those who were last exposed in the third trimester [n = 55] [2.9% vs 3.6%; p = 1.00]. All adverse events were spontaneously resolved and there were no serious adverse events such as active tuberculosis infection or death. Conclusions: BCG vaccination after 6 months of age is of low risk in infants exposed to anti-TNF agents in utero.
more